Literature DB >> 27802895

A connective tissue disorder may underlie ESSENCE problems in childhood.

Carolina Baeza-Velasco1, Rodney Grahame2, Jaime F Bravo3.   

Abstract

BACKGROUND: Ehlers-Danlos syndrome hypermobility type, also known as Joint Hypermobility Syndrome (EDS-HT/JHS), is the most common hereditary disorder of the connective tissue (HDCT). It is characterized by tissue fragility, joint hypermobility and a wide range of articular and non-articular manifestations, which often appear in infancy. The clinical picture of EDS-HT/JHS is poorly known by the medical community, as is the presence of "ESSENCE" (Early Symptomatic Syndromes Eliciting Neurodevelopmental Clinical Examinations) problems in affected children. AIM: The present work reviews the clinical and empirical evidence for ESSENCE difficulties in children with EDS-HT/JHS.
METHOD: A narrative review of the literature was undertaken following a comprehensive search of scientific online databases and reference lists. This included publications of quantitative and qualitative research.
RESULTS: Motor abnormality, hyperactivity/hypoactivity, inattention, speech/language, social interaction, behavioral, sleep, feeding and emotional problems are ESSENCE difficulties for which there is some evidence of an association with EDS-HT/JHS.
CONCLUSION: Children with EDS-HT/JHS present ESSENCE problems that often coexist and tend to be recognized before the HDCT. Clinicians encountering children with ESSENCE problems should consider the possibility of an underlying HDCT such as EDS-HT/JHS, probably influencing neurodevelopmental attributes in a subgroup of children. Awareness of these interconnected clinical problems might help improve early referral, diagnosis and treatment of EDS-HT/JHS.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  A typical brain development; Attention deficit; Developmental coordination disorder; ESSENCE; Ehlers-Danlos syndrome; Feeding; Hyperactivity; Hypoactivity; Joint hypermobility syndrome; Neurodevelopmental disorders; Sleep problems

Mesh:

Year:  2016        PMID: 27802895     DOI: 10.1016/j.ridd.2016.10.011

Source DB:  PubMed          Journal:  Res Dev Disabil        ISSN: 0891-4222


  7 in total

1.  Generalised joint hypermobility and neurodevelopmental traits in a non-clinical adult population.

Authors:  Martin Glans; Susanne Bejerot; Mats B Humble
Journal:  BJPsych Open       Date:  2017-09-27

Review 2.  The Relationship between Autism and Ehlers-Danlos Syndromes/Hypermobility Spectrum Disorders.

Authors:  Emily L Casanova; Carolina Baeza-Velasco; Caroline B Buchanan; Manuel F Casanova
Journal:  J Pers Med       Date:  2020-12-01

3.  Alterations in serum amino acid profiles in children with attention deficit/hyperactivity disorder.

Authors:  Anatoly V Skalny; Anna L Mazaletskaya; Irina P Zaitseva; Andrey A Skalny; Demetrios A Spandidos; Aristidis Tsatsakis; Yulia N Lobanova; Margarita G Skalnaya; Michael Aschner; Alexey A Tinkov
Journal:  Biomed Rep       Date:  2021-03-19

4.  The "Connectivome Theory": A New Model to Understand Autism Spectrum Disorders.

Authors:  Leonardo Zoccante; Marco Luigi Ciceri; Luigi Alberto Gozzi; Gianfranco Di Gennaro; Nicoletta Zerman
Journal:  Front Psychiatry       Date:  2022-02-07       Impact factor: 4.157

Review 5.  Connecting brain and body: Transdiagnostic relevance of connective tissue variants to neuropsychiatric symptom expression.

Authors:  Harriet Emma Clare Sharp; Hugo D Critchley; Jessica A Eccles
Journal:  World J Psychiatry       Date:  2021-10-19

6.  Motor Skill Improvement Using Compressive Garments in a Child with Multidimensional Impairments and Ehlers-Danlos Syndrome.

Authors:  Jean Xavier; Soizic Gauthier; Ingrid Zammouri; Salvatore Maria Anzalone; David Cohen
Journal:  Case Rep Psychiatry       Date:  2022-09-06

7.  Health-related quality of life and burden of illness in adults with newly diagnosed attention-deficit/hyperactivity disorder in Sweden.

Authors:  E Ahnemark; M Di Schiena; A-C Fredman; E Medin; J K Söderling; Y Ginsberg
Journal:  BMC Psychiatry       Date:  2018-07-13       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.